Wengenmayer Christina, Krikov Maxim, Mueller Susanne, Lucht Kristin, Villringer Arno, Hocher Berthold, Unger Thomas, Thoene-Reineke Christa
Center for Cardiovascular Research/ Institut fuer Pharmakologie, Charité-Universitaetsmedizin Berlin, Germany.
Neurol Res. 2011 Mar;33(2):201-7. doi: 10.1179/016164111X12881719352534.
Stroke, frequently a consequence of hypertension, is one of the leading causes of death and neurological disabilities worldwide. In the ischemic brain, levels of endothelin-1, one of the most potent vasoconstrictors, are raised. Anti-inflammatory and neuroprotective effects of endothelin antagonists after stroke have been described in literature. Based on these findings, we investigated the protective effect of the endothelin converting enzyme/neutral endopeptidase blocker, SLV 338, in salt-loaded, stroke-prone, spontaneously hypertensive rats.
Male, 8-week-old spontaneously hypertensive stroke-prone rats were put on a high salt diet and treated with either 30 mg/kg or 100 mg/kg SLV 338 or vehicle for 27 weeks. Blood pressure, neurological outcome, body weight, and mortality were investigated throughout treatment. In weeks 1 and 9, animals were housed in metabolic cages for collection of urinary and blood samples and assessment of salt water and food intake. In weeks 22 and 27, additional blood samples were taken. At the end of the study, all brains were analyzed using magnetic resonance imaging.
SLV 338 was well tolerated in all animals. Neurological outcome and infarct size were similar in all groups. Albuminuria was considerably delayed and the incidence of stroke significantly lowered in treated animals. In spontaneously hypertensive stroke-prone rats, treatment with SLV 338 significantly (P = 0·01) improved survival in comparison to the vehicle treated group in a blood pressure-independent manner.
Our data in spontaneously hypertensive stroke-prone rats demonstrate that combined endothelin converting enzyme/neutral endopeptidase inhibition could offer a new therapeutic approach for primary stroke prevention and improvement of mortality. The mechanism seems to be blood pressure-independent.
中风通常是高血压的后果,是全球范围内死亡和神经功能残疾的主要原因之一。在缺血性脑中,内皮素-1(最有效的血管收缩剂之一)的水平会升高。文献中已描述了中风后内皮素拮抗剂的抗炎和神经保护作用。基于这些发现,我们研究了内皮素转化酶/中性内肽酶阻滞剂SLV 338对高盐饮食、易中风的自发性高血压大鼠的保护作用。
将8周龄的雄性自发性高血压易中风大鼠置于高盐饮食中,并用30mg/kg或100mg/kg的SLV 338或赋形剂治疗27周。在整个治疗过程中监测血压、神经功能结局、体重和死亡率。在第1周和第9周,将动物置于代谢笼中以收集尿液和血液样本,并评估盐水和食物摄入量。在第22周和第27周,采集额外的血液样本。在研究结束时,使用磁共振成像分析所有大鼠的大脑。
所有动物对SLV 338耐受性良好。所有组的神经功能结局和梗死面积相似。治疗组动物的蛋白尿明显延迟,中风发生率显著降低。在自发性高血压易中风大鼠中,与赋形剂治疗组相比,SLV 338治疗以血压非依赖性方式显著(P = 0·01)提高了生存率。
我们在自发性高血压易中风大鼠中的数据表明,联合抑制内皮素转化酶/中性内肽酶可为原发性中风预防和死亡率改善提供一种新的治疗方法。其机制似乎与血压无关。